drug_type
RELEVANT_DRUG
intervention_type
Vaccine (mRNA, personalized neoantigen)
drug_description
A personalized neoantigen mRNA cancer vaccine designed to deliver patient-specific mRNA that is taken up by antigen-presenting cells, translated into neoantigen peptides, and presented via MHC I/II to prime CD8+ and CD4+ T-cell responses against tumor cells; administered by injection every 21 days (up to 9 cycles) after surgery alongside standard adjuvant therapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
RNA Vaccines
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Personalized mRNA encoding patient-specific tumor neoantigens is injected and taken up by antigen-presenting cells (e.g., dendritic cells). The mRNA is translated into neoantigen peptides that are processed and presented on MHC I and II, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells to recognize and kill tumor cells expressing those neoantigens and establish immune memory.
drug_name
iNeo-Vac-R01
nct_id_drug_ref
NCT06026774